In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xcyte Therapies Inc.

Division of Cyclacel Pharmaceuticals Inc.
www.xcytetherapies.com

Latest From Xcyte Therapies Inc.

Reverse Mergers Gain Traction In Tough IPO Times

Reverse mergers like Micromet's takeover of Cancervax and Cyclacel's takeover of Xcyte Therapies illustrate both tough times for IPO contenders as well as the innovative and sometimes win-win solution a reverse merger can provide.
BioPharmaceutical

Early Rewards for Careful Targeting in Oncology

Two early-stage cancer deals at the end of last year set a new high for European biotech pre-clinical deal dollars. They also highlighted the growing value, to Big Pharma and Big Biotech, of targeted, well-designed oncology leads, as progress in cancer therapeutics raises the hurdles for new products' potency and selectivity.
BioPharmaceutical Platform Technologies

IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?

Valuation Watch: an analysis of pre-money step ups for the 2003-04 biotech IPO window demonstrates that public investors are favoring companies in some therapeutic areas over companies in other areas. CNS and jump-start technologies, for example, are doing well.
BioPharmaceutical Strategy

Biotech's New Breed of IPOs

In assessing the sixteen biotechs making their public debuts over the past six months, investors clearly favor companies specializing in development, not discovery. What's more, investors especially prefer those development firms with late-stage products, lots of cash, and possibly even a sizable out-licensing deal.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cyclacel Pharmaceuticals Inc.
  • Senior Management
  • Ron Berenson, MD, Pres. & CEO
    Lewis P Chapman, CBO
  • Contact Info
  • Xcyte Therapies Inc.
    Phone: (206) 262-6200
    1124 Columbia St.
    Ste. 130
    Seattle, WA 98104
    USA
UsernamePublicRestriction

Register